Last 7 days
-6.6%
Last 30 days
-31.7%
Last 90 days
-34.7%
Trailing 12 Months
-9.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
SYK | 110.8B | 19.0B | -8.11% | 17.93% | 46.98 | 6.01 | 8.73% | 30.37% |
ISRG | 107.9B | 6.4B | 1.59% | 35.23% | 82.22 | 16.77 | 8.89% | -20.19% |
BSX | 74.1B | 13.0B | -2.50% | 25.53% | 106.12 | 5.84 | 7.26% | -32.95% |
BDX | 71.3B | 18.8B | -8.88% | -4.13% | 44.09 | 3.79 | -1.96% | -15.83% |
EW | 51.0B | 5.5B | -3.79% | -16.48% | 34.28 | 9.28 | 2.68% | -3.23% |
MID-CAP | ||||||||
SWAV | 7.2T | 557.2M | -4.80% | 67.52% | 82.2K | 16.8K | 86.42% | 730.06% |
PEN | 11.7B | 884.6M | 7.66% | 109.19% | 1.8K | 13.24 | 13.08% | 200.12% |
GMED | 5.9B | 1.1B | -6.80% | -18.72% | 34.14 | 5.75 | 11.20% | 53.04% |
IRTC | 3.5B | 430.0M | -14.11% | -18.87% | -33.26 | 8.1 | 26.13% | 15.73% |
TNDM | 1.7B | 794.7M | -34.98% | -61.87% | -8.24 | 2.11 | 7.73% | -3556.34% |
SMALL-CAP | ||||||||
ATEC | 1.7B | 389.0M | 2.85% | 97.40% | -11.25 | 4.42 | 44.08% | 6.96% |
SILK | 1.2B | 150.7M | -31.68% | -9.12% | -21.33 | 7.75 | 40.31% | 1.80% |
AVNS | 1.1B | 814.3M | -18.01% | -14.60% | 25.63 | 1.4 | 6.96% | 121.89% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 8.7% | 150,749 | 138,638 | 126,833 | 114,160 | 107,443 |
Gross Profit | 8.1% | 108,924 | 100,762 | 92,703 | 83,262 | 78,959 |
Operating Expenses | 6.0% | 161,884 | 152,766 | 146,139 | 140,763 | 132,218 |
S&GA Expenses | 5.9% | 123,125 | 116,317 | 111,391 | 107,619 | 102,468 |
R&D Expenses | 6.3% | 38,759 | 36,449 | 34,748 | 33,144 | 29,750 |
EBITDA | 0.9% | -46,892 | -47,295 | - | - | - |
EBITDA Margin | 6.7% | -0.41* | -0.44* | - | - | - |
EBT Margin | 5.9% | -0.44* | -0.46* | - | - | - |
Interest Expenses | 21.0% | 6,170 | 5,098 | 4,000 | 2,919 | 2,516 |
Net Income | 0.4% | -54,791 | -55,010 | -57,089 | -60,655 | -55,796 |
Net Income Margin | 11.8% | -0.40* | -0.45* | -0.53* | -0.52* | - |
Free Cahsflow | 20.8% | -37,586 | -47,479 | -49,991 | -48,451 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -3.7% | 260 | 270 | 163 | 163 | 143 |
Current Assets | -9.7% | 230 | 255 | 147 | 147 | 128 |
Cash Equivalents | -8.6% | 51.00 | 55.00 | 51.00 | 88.00 | 94.00 |
Inventory | -10.9% | 17.00 | 19.00 | 20.00 | 18.00 | 18.00 |
Net PPE | -5.1% | 9.00 | 9.00 | 10.00 | 10.00 | 10.00 |
Liabilities | -3.6% | 102 | 106 | 105 | 103 | 75.00 |
Current Liabilities | -14.8% | 21.00 | 24.00 | 24.00 | 21.00 | 29.00 |
. Short Term Borrowings | - | 10.00 | - | - | - | - |
LT Debt, Non Current | 0.3% | 75.00 | 75.00 | 74.00 | 74.00 | 39.00 |
Shareholder's Equity | -3.8% | 158 | 164 | 57.00 | 60.00 | 68.00 |
Retained Earnings | -4.8% | -360 | -343 | -331 | -320 | -305 |
Additional Paid-In Capital | 2.0% | 518 | 508 | 388 | 381 | 373 |
Shares Outstanding | 0.9% | 39.00 | 38.00 | 35.00 | 35.00 | 35.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 7.9% | -30.00 | -32.58 | -41.29 | -43.06 | -41.69 |
Share Based Compensation | 15.4% | 29.00 | 25.00 | 21.00 | 19.00 | 16.00 |
Cashflow From Investing | 5.0% | -153 | -162 | -42.87 | -2.00 | 34.00 |
Cashflow From Financing | 0.7% | 141 | 140 | 30.00 | 31.00 | 6.00 |
90.0%
87.2%
42.9%
Y-axis is the maximum loss one would have experienced if Silk Road Medical was unfortunately bought at previous high price.
-7.6%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | sold off | -100 | -255,160 | - | -% |
2023-05-23 | BROOKFIELD Corp /ON/ | sold off | -100 | -1,004,150 | - | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 1.01 | -1,065,360 | 3,162,640 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -73.87 | -3,218,000 | 772,000 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 99.87 | 2,608,000 | 8,040,000 | -% |
2023-05-17 | Thrivent Financial for Lutherans | added | 2.53 | -5,359,000 | 16,889,000 | 0.04% |
2023-05-17 | Advisory Services Network, LLC | reduced | -94.13 | -325,351 | 14,791 | -% |
2023-05-16 | Rockefeller Capital Management L.P. | sold off | -100 | -225,000 | - | -% |
2023-05-16 | Baker Avenue Asset Management, LP | unchanged | - | -206 | 587 | -% |
2023-05-16 | KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | added | 1.58 | -17,690,800 | 53,673,300 | 0.16% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
May 10, 2023 | wasatch advisors lp | - | 0 | SC 13G/A | |
Feb 14, 2023 | alliancebernstein l.p. | 6.9% | 2,616,795 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 7.8% | 2,966,730 | SC 13G/A | |
Feb 10, 2023 | flynn james e | 3.66% | 1,396,640 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.34% | 3,562,110 | SC 13G/A | |
Feb 08, 2023 | wasatch advisors inc | - | 0 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.0% | 2,664,762 | SC 13G/A | |
Apr 11, 2022 | alliancebernstein l.p. | 10.7% | 3,747,528 | SC 13G/A | |
Feb 14, 2022 | alliancebernstein l.p. | 8.6% | 2,988,334 | SC 13G/A | |
Feb 11, 2022 | capital world investors | 10.0% | 3,476,630 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 30, 2023 | SD | SD | |
May 15, 2023 | S-3ASR | S-3ASR | |
May 12, 2023 | 4 | Insider Trading | |
May 12, 2023 | RW | RW | |
May 11, 2023 | 144 | Notice of Insider Sale Intent | |
May 10, 2023 | SC 13G/A | Major Ownership Report | |
May 09, 2023 | 10-Q | Quarterly Report | |
May 09, 2023 | 8-K | Current Report | |
May 09, 2023 | S-3 | S-3 | |
May 03, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-11 | Rogers Erica J. | acquired | 4,800 | 1.6 | 3,000 | president and ceo |
2023-05-11 | Rogers Erica J. | sold | -106,530 | 35.51 | -3,000 | president and ceo |
2023-05-01 | Davis Andrew S. | sold | -300,593 | 44.5125 | -6,753 | chief commercial officer |
2023-05-01 | Davis Andrew S. | acquired | 39,844 | 5.90032 | 6,753 | chief commercial officer |
2023-04-17 | WEATHERMAN ELIZABETH H | sold | -209,550 | 41.91 | -5,000 | - |
2023-04-11 | Rogers Erica J. | sold | -238,635 | 39.7725 | -6,000 | president and ceo |
2023-04-11 | Rogers Erica J. | acquired | 9,600 | 1.6 | 6,000 | president and ceo |
2023-04-03 | Davis Andrew S. | acquired | 32,372 | 4.79376 | 6,753 | chief commercial officer |
2023-04-03 | Davis Andrew S. | sold | -266,203 | 39.42 | -6,753 | chief commercial officer |
2023-03-15 | WEATHERMAN ELIZABETH H | sold | -209,550 | 41.91 | -5,000 | - |
Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Condensed Statements of Operations and Comprehensive Loss [Abstract] | ||
Revenue | $ 40,131 | $ 28,021 |
Cost of goods sold | 12,526 | 8,577 |
Gross profit | 27,605 | 19,444 |
Operating expenses: | ||
Research and development | 10,433 | 8,123 |
Selling, general and administrative | 34,082 | 27,275 |
Total operating expenses | 44,515 | 35,398 |
Loss from operations | (16,910) | (15,954) |
Interest income | 2,287 | 12 |
Interest expense | (1,693) | (621) |
Other income (expense), net | (144) | (116) |
Net loss | (16,460) | (16,679) |
Other comprehensive loss: | ||
Change in unrealized gain (loss) on investments, net | 249 | |
Net change in other comprehensive loss | 249 | |
Net loss and comprehensive loss | $ (16,211) | $ (16,679) |
Net loss per share, basic | $ (0.43) | $ (0.48) |
Net loss per share, diluted | $ (0.43) | $ (0.48) |
Weighted average common shares used to compute net loss per share, basic | 38,532,202 | 35,023,297 |
Weighted average common shares used to compute net loss per share, diluted | 38,532,202 | 35,023,297 |
Condensed Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 50,427 | $ 55,358 |
Short-term investments | 138,640 | 158,316 |
Accounts receivable, net | 19,956 | 18,007 |
Inventories | 17,182 | 19,293 |
Prepaid expenses and other current assets | 4,049 | 3,924 |
Total current assets | 230,254 | 254,898 |
Long-term investments | 15,285 | |
Property and equipment, net | 8,897 | 9,372 |
Restricted cash | 155 | 155 |
Other non-current assets | 4,996 | 5,260 |
Total assets | 259,587 | 269,685 |
Current liabilities: | ||
Accounts payable | 5,272 | 2,523 |
Accrued liabilities | 15,598 | 21,965 |
Total current liabilities | 20,870 | 24,488 |
Long-term debt | 74,848 | 74,596 |
Other liabilities | 6,256 | 6,726 |
Total liabilities | 101,974 | 105,810 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value Shares authorized: 5,000,000 at March 31, 2023 and December 31, 2022 Shares issued and outstanding: none at March 31, 2023 and December 31, 2022 | ||
Common stock, $0.001 par value Shares authorized: 100,000,000 at March 31, 2023 and December 31, 2022 Shares issued and outstanding: 38,708,441 and 38,355,972 at March 31, 2023 and December 31, 2022, respectively | 39 | 38 |
Additional paid-in capital | 517,663 | 507,715 |
Accumulated other comprehensive income (loss) | 83 | (166) |
Accumulated deficit | (360,172) | (343,712) |
Total stockholders’ equity | 157,613 | 163,875 |
Total liabilities and stockholders’ equity | $ 259,587 | $ 269,685 |